ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA
Clinical trials for ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a new drug called veliparib combined with two chemotherapy drugs (cyclophosphamide and doxorubicin) in people with advanced solid tumors or non-Hodgkin lymphoma that has spread or cannot be removed. The main goal is to find the safest dose and underst…
Matched conditions: ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 05:32 UTC
-
New drug cocktail aims to boost lymphoma treatment
Disease control OngoingThis study tests adding a drug called vorinostat to the standard R-CHOP treatment for people with newly diagnosed, advanced-stage diffuse large B-cell lymphoma (DLBCL). The goal is to find the safest dose of vorinostat and see if the combination helps keep the cancer from coming …
Matched conditions: ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Gene test trial aims to personalize cancer care for kids
Knowledge-focused OngoingThis study screens children and young adults (ages 1-21) with advanced solid tumors, lymphomas, or related disorders that have not responded to standard therapy. Researchers analyze the genetic makeup of each patient's tumor to find specific mutations that can be targeted by cert…
Matched conditions: ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 17, 2026 05:28 UTC